Shares of Xtant Medical Holdings Inc (NASDAQ:XTNT) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price target of $5.33 for the company and are forecasting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also assigned Xtant Medical Holdings an industry rank of 103 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently issued reports on XTNT shares. Zacks Investment Research cut Xtant Medical Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, June 8th. HC Wainwright reissued a “buy” rating on shares of Xtant Medical Holdings in a report on Thursday, August 4th.

Shares of Xtant Medical Holdings (NASDAQ:XTNT) opened at 1.13 on Wednesday. Xtant Medical Holdings has a 1-year low of $0.93 and a 1-year high of $3.75. The stock has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.92. The company’s market capitalization is $13.78 million.

Xtant Medical Holdings Company Profile

Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.

5 Day Chart for NASDAQ:XTNT

Get a free copy of the Zacks research report on Xtant Medical Holdings (XTNT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Xtant Medical Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical Holdings Inc and related companies with's FREE daily email newsletter.